Table of Contents
COVID Resurgence and Increase in Confirmed Cases
The number of COVID-19 infections has been increasing for 11 consecutive weeks, raising concerns about a resurgence. According to data from the Korea Disease Control and Prevention Agency, the number of hospitalized patients between September 7 and 13 reached 460, a significant increase from just 63 at the end of June. In particular, those aged 65 and older now account for over 60% of all patients, indicating the infection is spreading primarily among high-risk groups.
Recent early symptoms of COVID-19 include sore throat, mild fever, diarrhea, fatigue, and insomnia. Current quarantine obligations have been lifted, but general individuals who are not high-risk must bear the testing costs themselves. Self-testing kits can be purchased for about 10,000 won, and treatment costs around 50,000 won over five days.
In this situation, COVID-related stocks are again drawing investor interest.
Major Companies Related to COVID Kits
Companies that are often highlighted during COVID-19 resurgences are primarily those that produce diagnostic kits. These companies are drawing significant interest in the market.
| Company Name | Main Features / Status Related to COVID Kits |
| Seegene (씨젠) | Produces PCR-based diagnostic kits. Responds to global demand with variant detection kits. |
| Humasis (휴마시스) | Supplier of self-testing kits. High volatility in stock prices during COVID resurgences. |
| LabGenomics (랩지노믹스) | Business in molecular diagnostic kits. High market responsiveness. |
| SD Biosensor (에스디바이오센서) | Leading domestic and international testing kit company. Sensitive to global demand. |
| PharmGen Science, Access Bio, Wells Bio | Expanding the diagnostic kit business through subsidiaries. Strong benefits expected upon demand recovery based on inventory. |
Due to the impact of COVID-19, these companies have the potential to profit and are often categorized as short-term theme stocks.
Seegene Chart Technical Analysis
Currently, Seegene's stock price is 26,600 won, which is about 27% lower than the recent peak of 36,650 won. Key points identified through chart analysis are as follows.
First, an observation of trends. A downward trend is prominent in the short term, but there is a sign of finding a support line near 26,000 won. The 20-day and 60-day moving averages are showing a downward trend, while the 120-day moving average is providing upper support.
Second, let’s look at the support and resistance zones. The main support line is at 25,000 won, functioning as a recent low and psychological support area. In contrast, the resistance line is at 29,000 won, where the 20-day line intersects with the volume level. If it exceeds 31,000 won in the medium term, it could signal a trend change.
An analysis of trading volume and auxiliary indicators is necessary.
The recent decrease in trading volume indicates a reduction in selling pressure. The RSI is nearing the oversold area, and the MACD is showing convergence from a low point. This suggests the possibility of a short-term rebound.
Comprehensive Judgment
COVID-19-related stocks, especially companies like Seegene, are significantly influenced by news and market sentiment, often experiencing rapid rises or falls in stock prices.
Currently, Seegene is at a point where a short-term rebound can be expected, with support at 25,000 won being a crucial factor. The short-term target price will be 29,000 won, and if it surpasses 31,000 won in the medium term, a reversal signal will appear.
Other related stocks such as Humasis, LabGenomics, and SD Biosensor are also likely to show short-term thematic trends based on the increase in confirmed cases.
Therefore, it is important to carefully observe the trends in confirmed cases, government policy changes, and trading volume when investing.
#COVIDResurgence, #COVIDConfirmedCases, #COVIDKitRelatedStocks, #Seegene, #Humasis, #LabGenomics, #SDBiosensor, #PharmGenScience, #AccessBio, #WellsBio, #COVIDDiagnosticKits, #SelfTestingKits, #PCRTest, #MolecularDiagnostics, #BiotechStocks, #PharmaceuticalBiotech, #InvestmentAnalysis, #ChartAnalysis, #TechnicalAnalysis, #COVIDSymptoms, #COVIDCosts, #TestingCosts, #Treatments, #Healthcare, #KCDC, #COVIDNews, #ThematicStocks, #Resurgence, #Quarantine, #InvestmentInformation
Frequently Asked Questions (FAQ)
Q. What is the trend of increasing infections due to the COVID-19 resurgence?
The number of COVID-19 infections has increased for 11 consecutive weeks, spreading primarily among the elderly.
Recently, COVID-19 infections have been increasing continuously for 11 weeks. In particular, high-risk individuals aged 65 and older account for over 60% of all patients and are showing a serious spread. The number of hospitalized patients has surged from 63 at the end of June to 460 in early September, raising concerns about a resurgence.
Q. What are the early symptoms and testing/treatment costs for COVID-19?
Early symptoms include sore throat, fever, diarrhea, and fatigue; self-testing kits cost about 10,000 won, and treatments cost about 50,000 won.
Early symptoms of COVID-19 include sore throat, mild fever, diarrhea, fatigue, and insomnia. Quarantine obligations have been lifted; however, general individuals must cover the testing costs out-of-pocket. The price of self-testing kits is around 10,000 won, and treatment costs about 50,000 won over five days.
Q. What are the major companies related to COVID diagnostic kits?
Major companies related to COVID kits include Seegene, Humasis, LabGenomics, and SD Biosensor.
Companies that produce diagnostic kits and are highlighted during COVID-19 resurgences include Seegene, Humasis, LabGenomics, and SD Biosensor. These companies are attracting investor interest in the biotech and pharmaceutical markets and tend to be classified as short-term theme stocks.
Q. What is the current technical status of Seegene's stock price?
Seegene's stock has fallen about 27%, but it is forming a support line at around 26,000 won, indicating a potential rebound.
Seegene's stock price has decreased from a recent peak of 36,000 won to about 26,600 won, representing approximately a 27% decline. The 20-day and 60-day moving averages are trending down; however, the 120-day moving average is providing upper support. The 25,000 won level is a significant support line, while 29,000 won acts as a resistance level that could signal a trend reversal if it exceeds 31,000 won in the medium term.
Q. What do Seegene's trading volume and auxiliary indicators suggest?
Decreasing trading volume, along with RSI and MACD indicators, suggests the potential for a short-term rebound.
The recent decrease in Seegene's trading volume indicates reduced selling pressure. The RSI indicator is approaching the oversold area, and the MACD shows convergence from a low point, which indicates a short-term rebound could be expected. This signals a positive outlook for investors.
Q. What should be noted when investing in COVID-related stocks?
It is essential to closely monitor confirmed case trends, government policy changes, and fluctuations in trading volume.
COVID-related stocks are significantly influenced by news and market sentiment, often experiencing rapid fluctuations. In particular, companies producing diagnostic kits, such as Seegene, are sensitive to increases in confirmed cases, changes in government quarantine policies, and fluctuations in trading volume. Therefore, it is essential to closely observe these factors while considering the characteristics of short-term theme stocks when investing.
